On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study

Arena Pharmaceuticals Inc. is on a roll, having revealed positive Phase II results for ralinepag in pulmonary arterial hypertension (PAH) followed by good Phase II data for etrasimod in ulcerative colitis (UC) – and now the company has encouraging results from a small exploratory study for its third clinical candidate, olorinab (APD371), in abdominal pain associated with Crohn's disease.

Arena is undergoing a long-term corporate makeover as it switches focus from the struggling obesity drug Belviq (lorcaserin) to other...